HAE · Company research
Haemonetics Corporation (HAE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Haemonetics Gains 149.3% in a Year: What's Driving the Rally? | Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Haemonetics Gains 149.3% in a Year: What's Driving the Rally? | Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - TradingView | Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term | Haemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term | Haemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us | Haemonetics Stock Price Forecast. Should You Buy HAE? StockInvest.us | View source ↗ | StockInvest.us | Oct 9, 2026 | neutral | 0 | 0.6 |
| Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada | Haemonetics Corporation (HAE) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? | Haemonetics shares surged 17.5% following CSL's announcement of a supply agreement rollout across U.S. plasma collection centers by end of 2027. The company expects Q earnings of $1.30 per share (+2.4% YoY) with revenues of $346.84 million (+6% YoY). However, analysts caution that without earnings estimate revisions, the stock may struggle to sustain momentum. HAE carries a Zacks Rank #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? | Haemonetics shares surged 17.5% following CSL's announcement of a supply agreement rollout across U.S. plasma collection centers by end of 2027. The company expects Q earnings of $1.30 per share (+2.4% YoY) with revenues of $346.84 million (+6% YoY). However, analysts caution that without earnings estimate revisions, the stock may struggle to sustain momentum. HAE carries a Zacks Rank #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? - Yahoo Finance Singapore | Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? - Yahoo Finance | Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Haemonetics (HAE) Jumped, What Is Behind The Move? - Yahoo Finance | Haemonetics (HAE) Jumped, What Is Behind The Move? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? - Stocktwits | HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics advances 17% on CSL supply deal (HAE:NYSE) - Seeking Alpha | Haemonetics advances 17% on CSL supply deal (HAE:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics (HAE) Shares Skyrocket, What You Need To Know - Yahoo Finance | Haemonetics (HAE) Shares Skyrocket, What You Need To Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside - StocksToTrade | Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside StocksToTrade | View source ↗ | StocksToTrade | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics (HAE) Stock Climbs After Citi Ups Price Target - Timothy Sykes | Haemonetics (HAE) Stock Climbs After Citi Ups Price Target Timothy Sykes | View source ↗ | Timothy Sykes | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Hits 52-Week High - Here's Why - Benzinga | Haemonetics Stock Hits 52-Week High - Here's Why Benzinga | View source ↗ | Benzinga | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Pops As Citi Hikes Price Target To $123 - StocksToTrade | Haemonetics Stock Pops As Citi Hikes Price Target To $123 StocksToTrade | View source ↗ | StocksToTrade | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics gains after update on CSL supply deal (HAE:NYSE) - Seeking Alpha | Haemonetics gains after update on CSL supply deal (HAE:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| A rollout to all current U.S. CSL plasma centers is anticipated for Haemonetics (HAE), subject to change. - Stock Titan | A rollout to all current U.S. CSL plasma centers is anticipated for Haemonetics (HAE), subject to change. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Hits 52-Week High - Here's Why - TradingView | Haemonetics Stock Hits 52-Week High - Here's Why TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| PAHC vs. HAE: Which Stock Is the Better Value Option? - Yahoo Finance | PAHC vs. HAE: Which Stock Is the Better Value Option? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Jumped 16% on a CSL Plasma Deal Yesterday. Here’s What Investors Need to Know. - TIKR.com | Haemonetics Stock Jumped 16% on a CSL Plasma Deal Yesterday. Here’s What Investors Need to Know. TIKR.com | View source ↗ | TIKR.com | Aug 19, 2026 | neutral | 0 | 0.6 |
| Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance - Yahoo Finance | Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance Yahoo Finance | View source ↗ | Yahoo Finance | Aug 15, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.